PE20010407A1 - Formulacion farmaceutica en capsulas de hidroxipropilmetilcelulosa - Google Patents

Formulacion farmaceutica en capsulas de hidroxipropilmetilcelulosa

Info

Publication number
PE20010407A1
PE20010407A1 PE2000000795A PE0007952000A PE20010407A1 PE 20010407 A1 PE20010407 A1 PE 20010407A1 PE 2000000795 A PE2000000795 A PE 2000000795A PE 0007952000 A PE0007952000 A PE 0007952000A PE 20010407 A1 PE20010407 A1 PE 20010407A1
Authority
PE
Peru
Prior art keywords
cpt
pharmaceutical formulation
hydroxypropyl methylcellulose
matrix
amino
Prior art date
Application number
PE2000000795A
Other languages
English (en)
Inventor
Paola Civaroli
Lorena Muggetti
Alessandro Martini
Original Assignee
Pharmacia Italia Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Italia Spa filed Critical Pharmacia Italia Spa
Publication of PE20010407A1 publication Critical patent/PE20010407A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE REFIERE A UNA FORMULACION ORAL QUE COMPRENDE UNA CAPSULA DE HIDROXIPROPILMETILCELULOSA: a)UN ANALOGO DE CAMPTOTECINA (CPT) DISPERSO O SOLUBILIZADO EN UNA MATRIZ SEMISOLIDA TAL COMO CPT-11, TOPOTECAN, 9-AMINO-20-CPT, 9-NITRO-20(S)-CPT UTILIZANDOSE 0,2 mg A 200 mg; SIENDO LA MATRIZ SEMISOLIDA UN POLIETILENGLICOL CON UN PESO MOLECULAR DE 400 A 20000 ADEMAS COMPRENDE UN EXCIPIENTE PARA LA MATRIZ SEMISOLIDA TAL COMO UN ACEITE, UN TENSIOACTIVO, UN POLOXAMERO, UN AGENTE SOLUBILIZANTE, UN GLICERIDO, UN FOSFOLIPIDO. LA COMPOSICION PUEDE SER UTIL PARA EL TRATAMIENTO DE ENFERMEDADES NEOPLASICAS, REDUCCION DE TUMORES, NEOPLASMAS, RECURRENCIAS DE CRECIMIENTOS TUMORALES O NEOPLASICOS, CANCER COLORECTAL
PE2000000795A 1999-08-10 2000-08-07 Formulacion farmaceutica en capsulas de hidroxipropilmetilcelulosa PE20010407A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9918885.6A GB9918885D0 (en) 1999-08-10 1999-08-10 Pharmaceutical formulations in hydroxypropymethycellulose capsules

Publications (1)

Publication Number Publication Date
PE20010407A1 true PE20010407A1 (es) 2001-03-28

Family

ID=10858930

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000795A PE20010407A1 (es) 1999-08-10 2000-08-07 Formulacion farmaceutica en capsulas de hidroxipropilmetilcelulosa

Country Status (18)

Country Link
US (1) US6569452B1 (es)
EP (1) EP1126851B1 (es)
CN (1) CN1245976C (es)
AR (1) AR025060A1 (es)
AT (1) ATE262905T1 (es)
AU (1) AU6158200A (es)
CA (1) CA2354039C (es)
CO (1) CO5200854A1 (es)
CZ (1) CZ293749B6 (es)
DE (1) DE60009442D1 (es)
EA (1) EA200100568A1 (es)
GB (1) GB9918885D0 (es)
HK (1) HK1040930B (es)
HU (1) HUP0104476A3 (es)
IL (2) IL143502A0 (es)
NO (1) NO319712B1 (es)
PE (1) PE20010407A1 (es)
WO (1) WO2001010443A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9925127D0 (en) * 1999-10-22 1999-12-22 Pharmacia & Upjohn Spa Oral formulations for anti-tumor compounds
CN1316970C (zh) * 2002-11-14 2007-05-23 武汉华中科大纳米药业有限公司 一种羟喜树碱固体分散物及其制剂
JP2005183361A (ja) * 2003-10-03 2005-07-07 Ngk Insulators Ltd 電子放出素子、電子放出装置、ディスプレイ及び光源
US20050208146A1 (en) * 2003-10-30 2005-09-22 Pfizer Inc Novel dosage and administration method for oral camptosar
GT200500310A (es) 2004-11-19 2006-06-19 Compuestos organicos
SA06270147B1 (ar) 2005-06-09 2009-12-22 نوفارتيس ايه جي عملية لتخليق 5-(مثيل–1h–إيميدازول–1-يل )–3-(ثلاثي فلـورو مثيل)–بنزامـين
WO2007033522A1 (fr) * 2005-09-21 2007-03-29 Shenzhen Tys R & D Co., Ltd. Formulation de gélule contenant de la moxifloxacine et son procédé de préparation
GB0526419D0 (en) * 2005-12-23 2006-02-08 Cyclacel Ltd Formulation
EP2086513B1 (en) * 2006-09-26 2016-09-07 Samyang Biopharmaceuticals Corporation Submicron nanoparticle of poorly water soluble camptothecin derivatives and process for preparation thereof
JP2014517046A (ja) * 2011-06-24 2014-07-17 アセンダ ファーマ インコーポレイテッド エステルプロドラッグの吸収を改善するための方法及び改善された医薬組成物
CN103110605A (zh) * 2011-11-17 2013-05-22 天士力制药集团股份有限公司 一种热熔胶囊制剂及其制备方法
US10143657B2 (en) * 2014-01-17 2018-12-04 Oncoral Pharma Aps Solid oral dosage form of irinotecan for the treatment of cancer
CN105287427B (zh) * 2015-10-20 2017-04-19 沈阳红旗制药有限公司 一种利福平半固体胶囊及其制备方法
KR102066402B1 (ko) * 2017-12-22 2020-01-15 대화제약 주식회사 이리노테칸 또는 그의 약제학적으로 허용가능한 염을 포함하는 경구투여용 약제학적 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4678516A (en) * 1984-10-09 1987-07-07 The Dow Chemical Company Sustained release dosage form based on highly plasticized cellulose ether gels
US5597829A (en) 1994-05-09 1997-01-28 Bionumerik Pharmaceuticals, Inc. Lactone stable formulation of camptothecin and methods for uses thereof
JP4177891B2 (ja) 1994-04-28 2008-11-05 バイオニューメリック ファーマシューティカルズ インク カンプトテシン又は７−エチルカンプトテシンのラクトン安定処方物
US5756123A (en) * 1994-12-01 1998-05-26 Japan Elanco Co., Ltd. Capsule shell
US5726181A (en) 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
EP0919228A4 (en) 1996-08-02 2001-12-12 Hisamitsu Pharmaceutical Co CAPSULES FOR ORAL PREPARATIONS AND CAPSULE PREPARATIONS FOR ORAL ADMINISTRATION
AR013261A1 (es) * 1997-08-01 2000-12-13 Smithkline Beecham Corp Formulaciones farmaceuticas para analogos de camptotecina en capsula de gelatina

Also Published As

Publication number Publication date
EP1126851B1 (en) 2004-03-31
CA2354039A1 (en) 2001-02-15
HK1040930B (zh) 2006-10-27
CZ20012089A3 (cs) 2001-10-17
NO319712B1 (no) 2005-09-05
CZ293749B6 (cs) 2004-07-14
CN1245976C (zh) 2006-03-22
EA200100568A1 (ru) 2001-10-22
IL143502A (en) 2006-12-10
CA2354039C (en) 2008-09-23
AU6158200A (en) 2001-03-05
HUP0104476A2 (hu) 2002-03-28
US6569452B1 (en) 2003-05-27
DE60009442D1 (de) 2004-05-06
CO5200854A1 (es) 2002-09-27
HUP0104476A3 (en) 2004-05-28
CN1327387A (zh) 2001-12-19
AR025060A1 (es) 2002-11-06
EP1126851A1 (en) 2001-08-29
HK1040930A1 (en) 2002-06-28
NO20013205D0 (no) 2001-06-26
IL143502A0 (en) 2002-04-21
GB9918885D0 (en) 1999-10-13
WO2001010443A1 (en) 2001-02-15
ATE262905T1 (de) 2004-04-15
NO20013205L (no) 2001-06-26

Similar Documents

Publication Publication Date Title
PE20010407A1 (es) Formulacion farmaceutica en capsulas de hidroxipropilmetilcelulosa
EP1061915A4 (en) PHARMACEUTICAL FORMULATIONS OF TAXANES
CZ309247B6 (cs) 40-O-(2-hydroxyethyl)rapamycin pro použití jako jediná účinná látka při léčení solidního nádoru
PE20040103A1 (es) Metodo y formas de dosificacion para incrementar la solubilidad de composiciones de farmaco para administracion controlada
AR022589A1 (es) UNA CÁPSULA QUE COMPRENDE UNA COMPOSICIoN FARMACÉUTICA ESPONTÁNEAMENTE DISPERSABLE PARA LA ADMINISTRACIoN ORAL, UNA COMPOSICIoN FARMACÉUTICA ESPONTÁNEAMENTE DISPERSABLE PARA LA ADMINISTRACIoN ORAL Y EL USO PARA LA PREPARACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DEL CÁNCER
ECSP045411A (es) Derivados de quinolinona
AR036448A1 (es) Composiciones farmaceuticas de conjugados droga insulina-oligomeros, y metodos para tratar las enfermedades con los mismos
MX2008009357A (es) Una composicion solida de taxano liofilizada, un procedimiento para preparar dicha composicion solida, una formulacion farmaceuctica y un conjunto (kit) de dicha formulacion.
WO2005065646A3 (en) Novel drug compositions and dosage forms
GB9713140D0 (en) Preparation of pharmaceutical compositions
CO5680109A1 (es) Compuestos para el tratamiento de la disfuncion sexual femenina
CO5560580A2 (es) Formulaciones de sucralosa para disumular sabores desagradables
CR6326A (es) Formulaciones farmaceuticas de liberacion controlada
UA91512C2 (ru) Коньюгати олигомеров инсулина, их композиция (варианты) и применение
ES2109899T1 (es) Metodo, composiciones y kits para aumentar la biodisponibilidad oral de agentes farmaceuticos.
NZ581589A (en) Solubilized sterile injectable formulation of docetaxel without Tween 80
EA200501819A1 (ru) Способы и фармацевтические композиции для достоверного достижения приемлемых уровней тестостерона в сыворотке
AR011133A1 (es) MICROGRÁNULOS DE LIBERACIoN CONTROLADA QUE CONTIENEN CISPLATINO , PROCEDIMIENTO DE SU PREPARACIoN, COMPOSICIoN FARMACÉUTICA Y UTILIZACIoN EN LA FABRICACIoN DE UN MEDICAMENTO POLIQUIMIOTERAPIA O EN ASOCIACIoN CON UNA RADIOTERAPIA.
RU2010110658A (ru) Композиции для лечения неопластических заболеваний
AR035946A1 (es) Composiciones farmaceuticas estrogenicas para usar en el tratamiento de desordenes en mujeres perimenopausicas, menopausicas o posmenopausicas, y usos de dichas composiciones para la preparacion de medicamentos
SE9603480L (sv) Beredningsform för svårlösliga läkemedel
MXPA06007510A (es) Composiciones de farmaco y formas de dosis novedosas de topiramato.
AR034142A1 (es) Una composicion farmaceutica, metodo para fabricar un medicamento en base a dicha composicion y uso de la composicion
WO2010019279A8 (en) Pharmaceutical compositions configured to deter dosage form splitting
GB9924636D0 (en) Laxative preparation

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed